中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.012 seconds)

    COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS
    1.
    发明申请
    COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS 审中-公开
    HSP60肽组成和病毒抗生素用于疫苗接种和诊断

    公开(公告)号：WO2006097914A3

    公开(公告)日：2007-01-04

    申请号：PCT/IL2006000222

    申请日：2006-02-21

    Applicant: YEDA RES & DEV ,  B G NEGEV TECHNOLOGIES AND APP ,  COHEN IRUN R ,  RAGER-ZISMAN BRACHA ,  PORGADOR ANGEL ,  HERKEL JOHANNES

    Inventor： COHEN IRUN R ,  RAGER-ZISMAN BRACHA ,  PORGADOR ANGEL ,  HERKEL JOHANNES

    IPC: A61K39/00 ,  C12Q1/70

    CPC classification number: A61K47/4833 ,  A61K47/646 ,  A61K2039/6043 ,  A61K2039/64 ,  C07K14/005 ,  C12N2770/24122 ,  G01N33/56983

    Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.

    Abstract translation: 本发明提供了包含分离的病毒抗原肽和衍生自HSP60的T细胞表位的合成肽的改进疫苗。 本发明包括其中肽用作佐剂以及其中肽与病毒抗原共价连接的缀合物的混合物。 已知的合成肽载体p458为合成的病毒表位和类似物提供显着改善的免疫原性。 Ec27是从HSP60衍生的新型肽，其作为混合物或共价缀合物增加了病毒抗原的免疫原性。 一些分离的病毒表位是新的，并且被要求用于诊断以及治疗或预防用途。

    NK CELL RECEPTOR CONJUGATES FOR TREATING MALIGNANCIES
    4.
    发明申请
    NK CELL RECEPTOR CONJUGATES FOR TREATING MALIGNANCIES 审中-公开

    公开(公告)号：WO2004053054A3

    公开(公告)日：2004-06-24

    申请号：PCT/IL2003/001040

    申请日：2003-12-09

    Applicant: NATSPEARS LTD. ,  MANDELBOIM, Ofer ,  PORGADOR, Angel

    Inventor： MANDELBOIM, Ofer ,  PORGADOR, Angel

    IPC: G01N33/53

    Abstract: The present invention relates generally to compositions useful in therapies involving the selective destruction of tumor cells in vivo. In particular, this invention relates to a conjugate which comprises a target recognition segment and an active cytotoxic segment. The target recognition segment comprises a receptor specific to NK cells, wherein the receptor binds to a cellular ligand expressed on the surface of a tumor cell, and the active segment comprises an agent capable of exerting a cytotoxic effect on the tumor cell. The target recognition segment derived form the natural killer receptor NKp30 has been found to be particularly effective in vivo.

    FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
    5.
    发明申请
    FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS 审中-公开
    NKp44和NKp46用于靶向病毒感染和肿瘤细胞的片段

    公开(公告)号：WO2005000086A2

    公开(公告)日：2005-01-06

    申请号：PCT/IL2004000583

    申请日：2004-06-30

    Applicant: YISSUM RES DEV CO ,  UNIV BEN GURION ,  MANDELBOIM OFER ,  PORGADOR ANGEL

    Inventor： MANDELBOIM OFER ,  PORGADOR ANGEL

    IPC: A61B20060101 ,  C07K14/705 ,  A61B

    CPC classification number: C07K14/70503 ,  A61K38/00 ,  C07K14/705 ,  C07K2319/01

    Abstract: The present invention relates generally to peptides derived from the natural cytotoxicity receptors on natural killer (NK) cells and to antibodies against peptide epitopes on these receptor. In particular, the present invention identifies an essential epitope in the proximal domain of NKp46 and NKp44 receptors present on NK cells, as a crucial element for the binding to viral-infected. The present invention provides peptides that are derived from the amino acid sequence of NKp46 receptor, capable of specific targeting of viral-infected cells and tumor cells and monoclonal antibodies which recognize a specific domain of NKp46. The present invention further provides hyperglycosylated peptides that are derived from the NKp44 receptor, capable of specific targeting of viral-infected cells.

    Abstract translation: 本发明一般涉及天然杀伤细胞（NK）细胞上衍生自天然细胞毒性受体的肽和针对这些受体上的肽表位的抗体。 特别地，本发明鉴定了存在于NK细胞上的NKp46和NKp44受体的近端结构域中的必需表位，作为与病毒感染结合的关键因素。 本发明提供衍生自NKp46受体的氨基酸序列的肽，其能够特异性靶向病毒感染的细胞和肿瘤细胞，以及识别NKp46的特异性结构域的单克隆抗体。 本发明进一步提供衍生自NKp44受体的能够特异性靶向病毒感染细胞的高糖基化肽。

Patent Agency Ranking